Cargando…

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

BACKGROUND: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moore, Amanda M, Nooruddin, Zohra, Reveles, Kelly R, Koeller, Jim M, Whitehead, Jennifer M, Franklin, Kathleen, Datta, Paromita, Alkadimi, Munaf, Brannman, Lance, Cotarla, Ion, Frankart, Andrew J, Mulrooney, Tiernan, Jones, Xavier, Frei, Christopher R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485300/ https://www.ncbi.nlm.nih.gov/pubmed/37335901 http://dx.doi.org/10.1093/oncolo/oyad172

Ejemplares similares

Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
por: Moore, Amanda M., et al.
Publicado: (2023)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014
por: Reveles, Kelly R., et al.
Publicado: (2017)

SEVERE COVID-19 ASSOCIATED WITH ADVANCED FORMS OF PULMONARY TB DISEASE IN AN ENDEMIC AREA OF ROMANIA
por: ARGHIR, I., et al.
Publicado: (2022)

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
por: Chouieri, Toni
Publicado: (2023)

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
por: Raez, Luis E., et al.
Publicado: (2022)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs
por: Lucero, Kana Tai, et al.
Publicado: (2023)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china
por: Jiang, Xiaotong, et al.
Publicado: (2022)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis
por: Machado, Felipe V C, et al.
Publicado: (2021)

Delays to surgery and worse outcomes: The compounding effects of social determinants of health in non–small cell lung cancer
por: Ashrafi, Arman, et al.
Publicado: (2023)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Comparative Value of Four Measures of Retention in Expert Care in Predicting Clinical Outcomes and Health Care Utilization in HIV Patients
por: Reveles, Kelly R., et al.
Publicado: (2015)

Is investigation of patients with haemoptysis and normal chest radiograph justified?
por: Thirumaran, M, et al.
Publicado: (2009)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines
por: Ryan, Bríd M
Publicado: (2016)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Cone beam CT-guided navigation bronchoscopy: a cost-effective alternative to CT-guided transthoracic biopsy for diagnosis of peripheral pulmonary nodules
por: Kops, Stephan E P, et al.
Publicado: (2022)

Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells
por: Ward, C, et al.
Publicado: (2009)

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
por: Dunlop, Will, et al.
Publicado: (2021)

The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease
por: Patel, Dhiren F., et al.
Publicado: (2018)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients
por: Reese, Peter P., et al.
Publicado: (2023)

A Prospective Observational Study of Hypogammaglobulinemia in the First Year After Lung Transplantation
por: Petrov, Andrej A., et al.
Publicado: (2018)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Lung Transplantation in Systemic Sclerosis: a Practice Survey of United States Lung Transplant Centers
por: Sehgal, Sameep, et al.
Publicado: (2021)

Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant
por: de Groot, Patricia M., et al.
Publicado: (2017)

Surviving White-out: How to Manage Severe Noninfectious Acute Lung Allograft Dysfunction of Unknown Etiology
por: Trindade, Anil J., et al.
Publicado: (2022)

The exposome concept: a challenge and a potential driver for environmental health research
por: Siroux, Valérie, et al.
Publicado: (2016)

Treatment of a Pulmonary Aspergilloma in a Lung Transplant Recipient Using Catheter-directed Intracavitary Instillation of Liposomal Amphotericin B
por: Courtwright, Andrew M., et al.
Publicado: (2021)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s4e7d13smuhvppkseplros6kr9